EUVIMEDEUVIMED entdecken
Crossref

Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention

Yi-Chieh Chen iD, Han Wang iD, Jayawant N Mandrekar, Carrie E Robertson iD, Amaal J Starling, Fred M Cutrer, Chia-Chun Chiang

The Pharmacogenomics Journal · 2024

DOI: 10.1038/s41397-024-00331-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Pharmacogenomics Journal, 2024. Verfasst von Yi-Chieh Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. Chen.Yi-Chieh@mayo.edu. Hauptthemen laut MEDLINE: Verapamil, Migraine Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate factors affecting the efficacy and tolerability of verapamil for migraine prevention using individual pharmacogenomic phenotypes. BACKGROUND: Verapamil has a wide range of dosing in headache disorders without reliable tools to predict the optimal doses for an individual. METHODS: This is a retrospective chart review examining adults with existing pharmacogenomic reports at Mayo Clinic who had used verapamil for migraine. Effects of six cytochrome P450 phenotypes on the doses of verapamil for migraine prevention were assessed. RESULTS: Our final analysis included 33 migraine patients (82% with aura). The mean minimum effective and maximum tolerable doses of verapamil were 178.2(20-320) mg and 227.9(20-480) mg. A variety of CYP2C9, CYP2D6, and CYP3A5 phenotypes were found, without significant association with the verapamil doses after adjusting for age, sex, body mass index, and smoking status. CONCLUSIONS: We demonstrated a wide range of effective and tolerable verapamil doses used for migraine in a cohort with various pharmacogenomic phenotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VerapamilMigraine DisordersAdultHumansPilot ProjectsPharmacogenomic TestingPharmacogeneticsRetrospective StudiesPhenotype

Substanzen

Verapamil

Autor:innen und Institutionen

  • Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. Chen.Yi-Chieh@mayo.edu.
  • Department of Neurology, Mayo Clinic Health System, Mankato, MN, USA.
  • Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA.

ORCID-Profile: Yi-Chieh Chen, Han Wang, Carrie E Robertson

Zitieren

APA

Chen, Y. C., Wang, H., Mandrekar, J. N., Robertson, C. E., Starling, A. J., Cutrer, F. M., & Chiang, C. C. (2024). Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention. The Pharmacogenomics Journal. https://doi.org/10.1038/s41397-024-00331-4

Vancouver

Chen YC, Wang H, Mandrekar JN, Robertson CE, Starling AJ, Cutrer FM, et al. Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention. The Pharmacogenomics Journal. 2024. doi:10.1038/s41397-024-00331-4

BibTeX
@article{Chen2024,
  author = {Chen, Yi-Chieh and Wang, Han and Mandrekar, Jayawant N and Robertson, Carrie E and Starling, Amaal J and Cutrer, Fred M and Chiang, Chia-Chun},
  title = {Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention},
  journal = {The Pharmacogenomics Journal},
  year = {2024},
  doi = {10.1038/s41397-024-00331-4}
}
Kostenlos starten →